649 related articles for article (PubMed ID: 14575972)
1. Genetic cause of hyperglycaemia and response to treatment in diabetes.
Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
Pearson ER; Liddell WG; Shepherd M; Corrall RJ; Hattersley AT
Diabet Med; 2000 Jul; 17(7):543-5. PubMed ID: 10972586
[TBL] [Abstract][Full Text] [Related]
3. beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations.
Pearson ER; Velho G; Clark P; Stride A; Shepherd M; Frayling TM; Bulman MP; Ellard S; Froguel P; Hattersley AT
Diabetes; 2001 Feb; 50 Suppl 1():S101-7. PubMed ID: 11272165
[TBL] [Abstract][Full Text] [Related]
4. Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations.
Pearson ER; Badman MK; Lockwood CR; Clark PM; Ellard S; Bingham C; Hattersley AT
Diabetes Care; 2004 May; 27(5):1102-7. PubMed ID: 15111528
[TBL] [Abstract][Full Text] [Related]
5. Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and hepatocyte nuclear factor 1alpha genes.
Elbein SC; Sun J; Scroggin E; Teng K; Hasstedt SJ
Diabetes Care; 2001 Mar; 24(3):472-8. PubMed ID: 11289470
[TBL] [Abstract][Full Text] [Related]
6. Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers.
Sagen JV; Pearson ER; Johansen A; Spyer G; Søvik O; Pedersen O; Njølstad PR; Hattersley AT; Hansen T
Diabet Med; 2005 Apr; 22(4):406-9. PubMed ID: 15787664
[TBL] [Abstract][Full Text] [Related]
7. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).
Boileau P; Wolfrum C; Shih DQ; Yang TA; Wolkoff AW; Stoffel M
Diabetes; 2002 Dec; 51 Suppl 3():S343-8. PubMed ID: 12475773
[TBL] [Abstract][Full Text] [Related]
8. Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation.
Hansen T; Eiberg H; Rouard M; Vaxillaire M; Møller AM; Rasmussen SK; Fridberg M; Urhammer SA; Holst JJ; Almind K; Echwald SM; Hansen L; Bell GI; Pedersen O
Diabetes; 1997 Apr; 46(4):726-30. PubMed ID: 9075819
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
10. The genetic abnormality in the beta cell determines the response to an oral glucose load.
Stride A; Vaxillaire M; Tuomi T; Barbetti F; Njølstad PR; Hansen T; Costa A; Conget I; Pedersen O; Søvik O; Lorini R; Groop L; Froguel P; Hattersley AT
Diabetologia; 2002 Mar; 45(3):427-35. PubMed ID: 11914749
[TBL] [Abstract][Full Text] [Related]
11. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice.
Pontoglio M; Sreenan S; Roe M; Pugh W; Ostrega D; Doyen A; Pick AJ; Baldwin A; Velho G; Froguel P; Levisetti M; Bonner-Weir S; Bell GI; Yaniv M; Polonsky KS
J Clin Invest; 1998 May; 101(10):2215-22. PubMed ID: 9593777
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
13. Different genes, different diabetes: lessons from maturity-onset diabetes of the young.
Stride A; Hattersley AT
Ann Med; 2002; 34(3):207-16. PubMed ID: 12173691
[TBL] [Abstract][Full Text] [Related]
14. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
15. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
Feng Y; Mao G; Ren X; Xing H; Tang G; Li Q; Li X; Sun L; Yang J; Ma W; Wang X; Xu X
Diabetes Care; 2008 Oct; 31(10):1939-44. PubMed ID: 18599530
[TBL] [Abstract][Full Text] [Related]
16. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers.
Stride A; Ellard S; Clark P; Shakespeare L; Salzmann M; Shepherd M; Hattersley AT
Diabetes Care; 2005 Jul; 28(7):1751-6. PubMed ID: 15983330
[TBL] [Abstract][Full Text] [Related]
17. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene.
Menzel R; Kaisaki PJ; Rjasanowski I; Heinke P; Kerner W; Menzel S
Diabet Med; 1998 Oct; 15(10):816-20. PubMed ID: 9796880
[TBL] [Abstract][Full Text] [Related]
18. Three new mutations in the hepatocyte nuclear factor-1alpha gene in Japanese subjects with diabetes mellitus: clinical features and functional characterization.
Yoshiuchi I; Yamagata K; Yang Q; Iwahashi H; Okita K; Yamamoto K; Oue T; Imagawa A; Hamaguchi T; Yamasaki T; Horikawa Y; Satoh T; Nakajima H; Miyazaki J; Higashiyama S; Miyagawa J; Namba M; Hanafusa T; Matsuzawa Y
Diabetologia; 1999 May; 42(5):621-6. PubMed ID: 10333057
[TBL] [Abstract][Full Text] [Related]
19. [High sensitivity to sulphonylurea treatment in 2 patients with maturity-onset diabetes of the young type 3].
Bosselaar M; Hattersley AT; Tack CJ
Ned Tijdschr Geneeskd; 2002 Apr; 146(15):726-9. PubMed ID: 11980375
[TBL] [Abstract][Full Text] [Related]
20. Glucose utilization and production in patients with maturity-onset diabetes of the young caused by a mutation of the hepatocyte nuclear factor-1alpha gene.
Surmely JF; Guenat E; Philippe J; Dussoix P; Schneiter P; Temler E; Vaxillaire M; Froguel P; Jéquier E; Tappy L
Diabetes; 1998 Sep; 47(9):1459-63. PubMed ID: 9726235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
